Synthesis of novel phenylacetic acid derivatives with halogenated benzyl subunit and evaluation as aldose reductase inhibitors

被引：11

作者：

Rakowitz, D ^{[1
]}

Gmeiner, A ^{[1
]}

Schröder, N ^{[1
]}

Matuszczak, B ^{[1
]}

机构：

[1] Univ Innsbruck, Inst Pharm, A-6020 Innsbruck, Austria

来源：

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2006年 / 27卷 / 2-3期

关键词：

aldose reductase; inhibitor; enzyme inhibitors; substituted phenylacetic acids;

D O I：

10.1016/j.ejps.2005.09.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the course of our ongoing studies several substituted benzyloxyphenylacetic acids were prepared. Comparison of their aldose reductase inhibition with the biological activity obtained for recently evaluated benzoic acid analogues revealed the critical role of a methylene spacer between the aromatic core and the acidic function. Starting from the most potent derivative (i.e. 5d, IC(50) = 20.9 mu M) further structural modifications were performed and their influence on the inhibitory effect was established. (C) 2005 Elsevier B.V. All rights reserved.

引用

页码：188 / 193

页数：6

共 13 条

[1] CHOU TC, 1996, CALCUSYN SOFTWARE VE
[2] New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications
Costantino, L
Rastelli, G
Cignarella, G
Vianello, P
Barlocco, D
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (08) : 843 - 858
[3] Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors
Costantino, L
Rastelli, G
Vescovini, K
Cignarella, G
Vianello, P
DelCorso, A
Cappiello, M
Mura, U
Barlocco, D
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (22) : 4396 - 4405
[4] Ultrahigh resolution drug design I:: Details of interactions in human aldose reductase-inhibitor complex at 0.66 Å
Howard, EI
Sanishvili, R
Cachau, RE
Mitschler, A
Chevrier, B
Barth, P
Lamour, V
Van Zandt, M
Sibley, E
Bon, C
Moras, D
Schneider, TR
Joachimiak, A
Podjarny, A
[J]. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2004, 55 (04) : 792 - 804
[5] The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat
Kinoshita, T
Miyake, H
Fujii, T
Takakura, S
Goto, T
[J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 : 622 - 626
[6] Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications
Miyamoto, S
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (05) : 621 - 631
[7] Modrakowski C, 2001, SYNTHESIS-STUTTGART, P2143
[8] Subatomic and atomic crystallographic studies of aldose reductase: implications for inhibitor binding
Podjarny, A
Cachau, RE
Schneider, T
Van Zandt, M
Joachimiak, A
[J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2004, 61 (7-8) : 763 - 773
[9] BALANCED AT(1)/AT(2) RECEPTOR ANTAGONISTS .4. XR510 AND RELATED 5-(3-AMIDOPROPANOYL)IMIDAZOLES POSSESSING EQUAL AFFINITY FOR THE AT(1) AND AT(2) RECEPTORS
QUAN, ML
CHIU, AT
ELLIS, CD
WONG, PC
WEXLER, RR
TIMMERMANS, PBMWM
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (15) : 2938 - 2945
[10] Synthesis of novel benzoic acid derivatives with benzothiazolyl subunit and evaluation as aldose reductase inhibitors
Rakowitz, D
Hennig, B
Nagano, M
Steger, S
Costantino, L
Matuszczak, B
[J]. ARCHIV DER PHARMAZIE, 2005, 338 (09) : 411 - 418

← 1 2 →